Featured Articles
Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10). CRISPR (an acronym for “clustered regularly […]
Read full story***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH), valued at up to €2 million. The Research Call seeks proposals from suitably qualified clinical investigators to address the current clinical uncertainty in respect of the medical management of sub-macular […]
Read full storyFindings from an international genomics consortium almost double the number of associated genetic loci and variants for AMD
Research conducted by the International AMD Genomics Consortium (IAMDGC) has recently reported an almost doubling in the number of genetic risk loci associated with age-related macular degeneration (AMD). In a significant publication in the journal Nature Genetics, the research group has reported on an analysis of >12 million gene variants, “including 163,714 directly genotyped, mostly […]
Read full story